TEMIS has acquired U.S.-based advanced analytics and visualization technology firm i3 Analytics. The latter provides a software-as-a-service (SaaS) ‘Biopharma Navigator’ platform that charts the biopharma landscape based on open life sciences data. We found this article on Mr. Web in their article, “TEMIS Buys i3 Analytics.”
TEMIS will integrate i3’s platform into its flagship Luxid product, which is used to semantically enrich content with domain-specific metadata. According to Eric Brégand, CEO of TEMIS, ‘This transaction creates a best-in-class offering for our life sciences customers, based on the winning combination of deep computational linguistics expertise and leading-edge data visualization know-how. And we will be transposing the solution to other verticals where data analytics and information visualization are also becoming critical.”
Melody K. Smith
Sponsored by Access Innovations, the world leader in taxonomies, metadata, and semantic enrichment to make your content findable.
